Infectious Disorders - Drug Targets aims to cover all the latest and outstanding developments in medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in infectious disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews/mini-reviews and research articles written by leaders in the field covering a range of current topics on drug targets involved in infectious disorders. As the discovery, identification, characterization and validation of novel human drug targets for anti-infective drug discovery continue to grow, this journal will be essential reading for all pharmaceutical scientists involved in drug design, discovery and development.
Jean-Marc Sabatier Laboratoire ERT 62 'Ingénierie des peptides à visée thérapeutique' Université de la Méditerranée Faculté de Médecine Nord Boulevard Pierre Dramard 13916 - MARSEILLE, Cedex 20 France
Jean-Marc SABATIER is a Director of research at the French CNRS, with PhD and HDR degrees in Biochemistry and Microbiology. He headed several academic research teams (CNRS, INSERM and University), as well as a combined academic-industry research laboratory devoted to the engineering of therapeutic peptides (ERT62, Marseilles, France). He was also a Director of Research for several French private companies as well as a Canadian public company. He acts as a Consultant for top pharmaceutical and cosmetic companies. Dr. Sabatier works in the field of animal toxins. He so far contributed to several books in toxinology and virology, and more than 160 scientific articles, 180 communications, and 53 patents in both biology and chemistry.